Emerging Evidence Concerning Systemic Safety of Anti-VEGF Agents – Should Ophthalmologists Be Concerned?
Intraocular injections of anti–vascular endothelial growth factor (VEGF) agents have yielded dramatic improvements in the management of a wide variety of neovascular ocular diseases including age-related macular degeneration (AMD), diabetic…
